# S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy

> **NCT00066612** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 45 (actual)

## Conditions studied

- Bladder Cancer
- Transitional Cell Cancer of the Renal Pelvis and Ureter
- Urethral Cancer

## Interventions

- **DRUG:** irinotecan hydrochloride

## Key facts

- **NCT ID:** NCT00066612
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-07
- **Primary completion:** 2007-08
- **Final completion:** 2010-05
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2012-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00066612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00066612, "S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00066612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*